HomeAI · summaries
Storia in 2 fonti
Novo Nordisk flags drug trial promise amid hunt for next weight-loss blockbuster
Phase 3 trial results showed the once-weekly Cagrilintide monotherapy injection helped patients reduce their weight by 11.8% on average after 68 weeks.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
cnbc.com
Novo Nordisk flags drug trial promise amid hunt for next weight-loss blockbuster
Phase 3 trial results showed the once-weekly Cagrilintide monotherapy injection helped patients reduce their weight by 11.8% on average after 68 weeks.
- ·
Novo Nordisk shares pop 5% after Wegovy pill trial shows 'significant' weight reduction
Trial results showed the "Wegovy pill" led to average weight reduction of 16.6% after 64 weeks, Novo Nordisk said.
- ·
theguardian.com
Novo Nordisk shares climb after positive results for anti-obesity pill
Danish drugmaker jumps by about £9bn as trial shows ‘significant weight loss’ with tablet version of Wegovy